ArticleFrontiers in oncology2026
Umbilical cord blood infusion enhances hematopoietic recovery and improves survival in elderly AML patients with chemotherapy-induced myelosuppression: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elderly AML (Acute Myeloid Leukemia) patients exhibit increased mortality owing to chemotherapy-induced myelosuppression. Umbilical cord blood (UCB) contains hematopoietic stem/progenitor cells and a spectrum of regenerative cytokines that actively promote hematopoietic regeneration. We investigated whether umbilical cord blood (UCB) infusion enhances hematopoietic recovery in elderly AML patients who experience chemotherapy-induced myelosuppression during post-chemotherapy supportive care. Methods: We retrospectively analyzed 95 elderly patients with AML in complete remission (CR1) who previously developed grade III-IV chemotherapy-induced myelosuppression. The control group (n=60) received standard supportive care, including granulocyte colony-stimulating factor (G-CSF), blood product transfusions, and antibiotic therapy. The experimental group (n = 35) underwent infusion of unrelated umbilical cord blood (UCB; CD34 Results: Neutrophil recovery duration (≥1.0×10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.